Blood

Vol. 146, Issue 8 Issue 8 2025
19
Articles

Articles in this Issue

Deep dive into shallow myeloma cell pool

Mehmet K. Samur Aug 21, 2025 pp. 906-907 10.1182/blood.2025029778

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Marta Lasa, Carmen González, Laura Notarfranchi et al. Aug 21, 2025 pp. 964-970 10.1182/blood.2025029234

Abstract The continuous improvement in progression-free survival (PFS) of patients with multiple myeloma (MM) raises interest in evaluating peripheral residual disease (PRD) toward m...

The landscape of disease: mapping aplastic anemia

Patrick M. Brunner Aug 21, 2025 pp. 905-906 10.1182/blood.2025029791

Checkpoint-primed allo-HCT in HL: cure gains, risk remains

Paul J. Bröckelmann, Bastian von Tresckow Aug 21, 2025 pp. 911-912 10.1182/blood.2025029908

When TNFα is out, IFN-γ drives anemia of inflammation

Laura Silvestri Aug 21, 2025 pp. 908-910 10.1182/blood.2025030006

Cracking the POD24 code in follicular lymphoma

Florian Scherer Aug 21, 2025 pp. 899-900 10.1182/blood.2025029930

A burden too high for CAR T cells in CLL

Arnon P. Kater, Maria Themeli Aug 21, 2025 pp. 901-902 10.1182/blood.2025029368

Protecting the epithelium and taming GVHD

Yishan Ye, Mohamad Mohty Aug 21, 2025 pp. 903-905 10.1182/blood.2025029271

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Miguel-Angel Perales, Farrukh T. Awan, Ariane Boumendil et al. Aug 21, 2025 pp. 1011-1029 10.1182/blood.2024027197

Abstract Checkpoint inhibitors (CPIs) have shown remarkable efficacy in Hodgkin lymphoma (HL), and are now used routinely. While allogeneic hematopoietic cell transplantation (allo-H...

The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice

Weiqing Jing, Jocelyn A. Schroeder, Saurabh Kumar et al. Aug 21, 2025 pp. 998-1010 10.1182/blood.2025029470

Abstarct Developing anti–factor VIII (FVIII) inhibitory antibodies (inhibitors) are a significant complication of FVIII protein replacement therapy in hemophilia A. Our previous stud...

CALR-ifying ATF6/BCL-xL activation by type 2 CALR mutations

Fan He, Stephen T. Oh Aug 21, 2025 pp. 907-908 10.1182/blood.2025029864

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms

Nicole S. Arellano, William L. Heaton, Mirielle C. Nauman et al. Aug 21, 2025 pp. 971-983 10.1182/blood.2024026940

Abstract Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52–base pair deletion (CALRdel52); or type 2, a 5–base pair insertion (...

Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies

Gerard Socie Aug 21, 2025 pp. 926-937 10.1182/blood.2025028617

Abstract Although allogeneic hematopoietic stem cell transplantation is a leading treatment approach for myeloid malignancies, challenges in its immune biology and in treatment appro...

TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation

Amaliris Guerra, Vania lo Presti, Ding-Wen Chen et al. Aug 21, 2025 pp. 984-997 10.1182/blood.2025029352

Abstract Anemia of inflammation (AI) is the second most common form of anemia and is prevalent in patients with chronic inflammatory states, such as infection, autoimmunity, and canc...

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy et al. Aug 21, 2025 pp. 913-925 10.1182/blood.2024027727

Abstract Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response...

Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia

Emma S. Pool, Sietse J. Luk, Marieke E. Ijsselsteijn et al. Aug 21, 2025 pp. 951-963 10.1182/blood.2025028723

Abstract The autoimmune response driving hematopoietic stem and progenitor cell (HSPC) destruction in immune-mediated aplastic anemia (AA) remains incompletely understood. We previou...

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia

Matthew S. Davids, Saad S. Kenderian, Ian Flinn et al. Aug 21, 2025 pp. 938-943 10.1182/blood.2024027460

Abstract ZUMA-8 evaluated the safety of brexucabtagene autoleucel (brexu-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapy, for patients with rela...

Allo-HCT in Hodgkin lymphoma after CPI

Aug 21, 2025 pp. 1030-1030 10.1182/blood.2025030720

Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT

Eduard Schulz, Lauren M. Curtis, Noa G. Holtzman et al. Aug 21, 2025 pp. 944-950 10.1182/blood.2024028303

Abstract Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT). Palifermin, a recombinant N-truncated keratinocyte growth fa...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page